
John M. Hoffmann
Examiner (ID: 5190, Phone: (571)272-1191 , Office: P/1741 )
| Most Active Art Unit | 1731 |
| Art Unit(s) | 1712, 1731, 1741, 1791, 1304, 1303 |
| Total Applications | 1565 |
| Issued Applications | 722 |
| Pending Applications | 142 |
| Abandoned Applications | 703 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 18978863
[patent_doc_number] => 11904017
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-02-20
[patent_title] => Methods for reducing or eliminating the need for lipoprotein apheresis in patients with hyperlipidemia by administering alirocumab
[patent_app_type] => utility
[patent_app_number] => 16/991269
[patent_app_country] => US
[patent_app_date] => 2020-08-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 8
[patent_figures_cnt] => 8
[patent_no_of_words] => 21667
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 126
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16991269
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/991269 | Methods for reducing or eliminating the need for lipoprotein apheresis in patients with hyperlipidemia by administering alirocumab | Aug 11, 2020 | Issued |
Array
(
[id] => 16613706
[patent_doc_number] => 20210032359
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-02-04
[patent_title] => ANTIBODIES AGAINST PHOSPHORYLCHOLINE IN COMBINATION THERAPY WITH BIOLOGIC AGENTS
[patent_app_type] => utility
[patent_app_number] => 16/990473
[patent_app_country] => US
[patent_app_date] => 2020-08-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13359
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -1
[patent_words_short_claim] => 113
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16990473
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/990473 | ANTIBODIES AGAINST PHOSPHORYLCHOLINE IN COMBINATION THERAPY WITH BIOLOGIC AGENTS | Aug 10, 2020 | Abandoned |
Array
(
[id] => 17865489
[patent_doc_number] => 20220288224
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-09-15
[patent_title] => PHARMACEUTICAL AGENT FOR TRANSMUCOSAL ADMINISTRATION
[patent_app_type] => utility
[patent_app_number] => 17/632785
[patent_app_country] => US
[patent_app_date] => 2020-08-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 3271
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -3
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17632785
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/632785 | PHARMACEUTICAL AGENT FOR TRANSMUCOSAL ADMINISTRATION | Aug 3, 2020 | Abandoned |
Array
(
[id] => 17837800
[patent_doc_number] => 20220275105
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-09-01
[patent_title] => NEUTRALIZING GRANZYME B FOR PROVIDING CARDIOPROTECTION IN A SUBJECT WHO EXPERIENCED A MYOCARDIAL INFARCTION
[patent_app_type] => utility
[patent_app_number] => 17/632271
[patent_app_country] => US
[patent_app_date] => 2020-07-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8447
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -5
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17632271
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/632271 | NEUTRALIZING GRANZYME B FOR PROVIDING CARDIOPROTECTION IN A SUBJECT WHO EXPERIENCED A MYOCARDIAL INFARCTION | Jul 30, 2020 | Pending |
Array
(
[id] => 16686850
[patent_doc_number] => 20210069325
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-03-11
[patent_title] => METHODS OF TREATING IMMUNE DISORDERS USING PD-1 BINDING PROTEINS
[patent_app_type] => utility
[patent_app_number] => 16/945706
[patent_app_country] => US
[patent_app_date] => 2020-07-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 124884
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16945706
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/945706 | METHODS OF TREATING IMMUNE DISORDERS USING PD-1 BINDING PROTEINS | Jul 30, 2020 | Abandoned |
Array
(
[id] => 16613704
[patent_doc_number] => 20210032357
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-02-04
[patent_title] => CD20 BINDING MOLECULES AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/938066
[patent_app_country] => US
[patent_app_date] => 2020-07-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 29259
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -27
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16938066
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/938066 | CD20 BINDING MOLECULES AND USES THEREOF | Jul 23, 2020 | Abandoned |
Array
(
[id] => 16870128
[patent_doc_number] => 20210163595
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-06-03
[patent_title] => METHODS OF TREATING VITILIGO USING PD-1 BINDING ANTIBODIES
[patent_app_type] => utility
[patent_app_number] => 16/930238
[patent_app_country] => US
[patent_app_date] => 2020-07-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 105371
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16930238
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/930238 | METHODS OF TREATING VITILIGO USING PD-1 BINDING ANTIBODIES | Jul 14, 2020 | Abandoned |
Array
(
[id] => 17775045
[patent_doc_number] => 20220241394
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-08-04
[patent_title] => TREATMENT OF DISEASES ASSOCIATED WITH PROTEIN MISFOLDING BY NERVOUS SYSTEM EXPRESSION OF AN ENZYME WHICH HAS A DEOXYRIBONUCLEASE (DNase) ACTIVITY
[patent_app_type] => utility
[patent_app_number] => 17/626616
[patent_app_country] => US
[patent_app_date] => 2020-07-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 34883
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -137
[patent_words_short_claim] => 41
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17626616
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/626616 | TREATMENT OF DISEASES ASSOCIATED WITH PROTEIN MISFOLDING BY NERVOUS SYSTEM EXPRESSION OF AN ENZYME WHICH HAS A DEOXYRIBONUCLEASE (DNase) ACTIVITY | Jul 9, 2020 | Pending |
Array
(
[id] => 18233212
[patent_doc_number] => 11597761
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-03-07
[patent_title] => Methods of detecting polyubiquitin using anti-polyubiquitin antibodies
[patent_app_type] => utility
[patent_app_number] => 16/914996
[patent_app_country] => US
[patent_app_date] => 2020-06-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 38
[patent_figures_cnt] => 38
[patent_no_of_words] => 47760
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 943
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16914996
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/914996 | Methods of detecting polyubiquitin using anti-polyubiquitin antibodies | Jun 28, 2020 | Issued |
Array
(
[id] => 19210731
[patent_doc_number] => 11999779
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-06-04
[patent_title] => Anti-complement factor C1q Fab fragments and uses thereof
[patent_app_type] => utility
[patent_app_number] => 16/911954
[patent_app_country] => US
[patent_app_date] => 2020-06-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 3
[patent_figures_cnt] => 2
[patent_no_of_words] => 24652
[patent_no_of_claims] => 19
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 54
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16911954
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/911954 | Anti-complement factor C1q Fab fragments and uses thereof | Jun 24, 2020 | Issued |
Array
(
[id] => 16360759
[patent_doc_number] => 20200317510
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-10-08
[patent_title] => ANTIBODIES SPECIFICALLY BINDING TO MASP-3 FOR THE TREATMENT OF VARIOUS DISEASES AND DISORDERS
[patent_app_type] => utility
[patent_app_number] => 16/909578
[patent_app_country] => US
[patent_app_date] => 2020-06-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 103541
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -27
[patent_words_short_claim] => 63
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16909578
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/909578 | Antibodies specifically binding to MASP-3 for the treatment of various diseases and disorders | Jun 22, 2020 | Issued |
Array
(
[id] => 17749645
[patent_doc_number] => 20220227849
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-07-21
[patent_title] => INHIBITOR OF SURFACE PROTEIN (SP-D) / SIRPA / SHP2 PATHWAY FOR USE IN THE PREVENTION AND/OR TREATMENT OF SECONDARY INFECTION
[patent_app_type] => utility
[patent_app_number] => 17/596958
[patent_app_country] => US
[patent_app_date] => 2020-06-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 21106
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17596958
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/596958 | INHIBITOR OF SURFACE PROTEIN (SP-D) / SIRPA / SHP2 PATHWAY FOR USE IN THE PREVENTION AND/OR TREATMENT OF SECONDARY INFECTION | Jun 22, 2020 | Pending |
Array
(
[id] => 17760073
[patent_doc_number] => 20220233685
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-07-28
[patent_title] => COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND ANTI-PD-1 ANTIBODY
[patent_app_type] => utility
[patent_app_number] => 17/596774
[patent_app_country] => US
[patent_app_date] => 2020-06-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 32953
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 133
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17596774
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/596774 | COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND ANTI-PD-1 ANTIBODY | Jun 17, 2020 | Abandoned |
Array
(
[id] => 17882753
[patent_doc_number] => 20220298230
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-09-22
[patent_title] => ANTIBODIES AND METHODS FOR TREATMENT OF VIRAL INFECTIONS
[patent_app_type] => utility
[patent_app_number] => 17/617901
[patent_app_country] => US
[patent_app_date] => 2020-06-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 43456
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -43
[patent_words_short_claim] => 17
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17617901
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/617901 | ANTIBODIES AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | Jun 3, 2020 | Pending |
Array
(
[id] => 19273247
[patent_doc_number] => 12023354
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-07-02
[patent_title] => Targeting B cell activating factor receptor (BAFF-R) using ligand-based chimeric antigen receptor (CAR)-T cells
[patent_app_type] => utility
[patent_app_number] => 16/888989
[patent_app_country] => US
[patent_app_date] => 2020-06-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 9
[patent_figures_cnt] => 10
[patent_no_of_words] => 7659
[patent_no_of_claims] => 13
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 30
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16888989
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/888989 | Targeting B cell activating factor receptor (BAFF-R) using ligand-based chimeric antigen receptor (CAR)-T cells | May 31, 2020 | Issued |
Array
(
[id] => 19410607
[patent_doc_number] => 12076400
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-09-03
[patent_title] => Methods of using a bispecific antigen-binding construct targeting HER2 in combination with CDK4/6 inhibitors for the treatment of breast cancer
[patent_app_type] => utility
[patent_app_number] => 16/887460
[patent_app_country] => US
[patent_app_date] => 2020-05-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 3
[patent_figures_cnt] => 3
[patent_no_of_words] => 39238
[patent_no_of_claims] => 18
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 176
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16887460
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/887460 | Methods of using a bispecific antigen-binding construct targeting HER2 in combination with CDK4/6 inhibitors for the treatment of breast cancer | May 28, 2020 | Issued |
Array
(
[id] => 16727902
[patent_doc_number] => 20210095049
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-04-01
[patent_title] => METHOD OF INHIBITING ECTOPIC CALCIFICATION
[patent_app_type] => utility
[patent_app_number] => 16/876350
[patent_app_country] => US
[patent_app_date] => 2020-05-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 3217
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -4
[patent_words_short_claim] => 73
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16876350
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/876350 | METHOD OF INHIBITING ECTOPIC CALCIFICATION | May 17, 2020 | Abandoned |
Array
(
[id] => 18666307
[patent_doc_number] => 11773185
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-10-03
[patent_title] => Anti-BACE1 antibodies and methods of use thereof
[patent_app_type] => utility
[patent_app_number] => 16/867942
[patent_app_country] => US
[patent_app_date] => 2020-05-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 7
[patent_figures_cnt] => 13
[patent_no_of_words] => 96637
[patent_no_of_claims] => 22
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 68
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16867942
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/867942 | Anti-BACE1 antibodies and methods of use thereof | May 5, 2020 | Issued |
Array
(
[id] => 16253532
[patent_doc_number] => 20200262906
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-08-20
[patent_title] => ANTIBODIES AGAINST PHOSPHORYLCHOLINE IN COMBINATION THERAPY WITH BIOLOGIC AGENTS
[patent_app_type] => utility
[patent_app_number] => 16/868323
[patent_app_country] => US
[patent_app_date] => 2020-05-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13341
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -1
[patent_words_short_claim] => 65
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16868323
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/868323 | ANTIBODIES AGAINST PHOSPHORYLCHOLINE IN COMBINATION THERAPY WITH BIOLOGIC AGENTS | May 5, 2020 | Abandoned |
Array
(
[id] => 17214575
[patent_doc_number] => 20210347912
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-11-11
[patent_title] => YKL-40 ANTIBODY
[patent_app_type] => utility
[patent_app_number] => 16/867050
[patent_app_country] => US
[patent_app_date] => 2020-05-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9413
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 150
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16867050
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/867050 | YKL-40 antibody | May 4, 2020 | Issued |